Text Size
11 studies found for:    pegylated liposomal doxorubicin AND carboplatin AND ovarian cancer | Open Studies

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Recruiting BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Ovarian Cancer (OC)
Conditions: Ovarian Neoplasms;   Peritoneal Neoplasms
Interventions: Drug: BIBF 1120 + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min;   Drug: BIBF 1120+ PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min
2 Recruiting SGI-110 in Combination With Carboplatin in Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Drug: SGI-110 and carboplatin;   Drug: Treatment of Choice ( topotecan, pegylated liposomal doxorubicin, or paclitaxel)
3 Recruiting Carboplatin-based Chemotherapy With or Without Panitumumab in Platinum-sensitive Recurrent Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Drug: Panitumumab;   Drug: pegylated liposomal doxorubicin (PLD);   Drug: Carboplatin;   Drug: Gemcitabine
4 Not yet recruiting Evaluation of Optimal Treatment With Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer
Condition: Recurrent Platinum-sensitive Ovarian Cancer
Interventions: Drug: Carboplatin;   Drug: PLD;   Biological: Bevacizumab
5 Not yet recruiting Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer
Condition: Recurrent Ovarian Cancer
Interventions: Drug: Bevacizumab;   Drug: Paclitaxel;   Drug: Carboplatin;   Drug: pegylated liposomal doxorubicin;   Drug: Gemcitabine
6 Recruiting Efficacy Study of Chemotherapy to Treat Ovarian Cancer Recurrence by Prolonging the Platinum Free Interval
Condition: Ovarian Cancer
Interventions: Drug: stealth liposomal doxorubicin;   Drug: carboplatin;   Drug: paclitaxel;   Drug: Topotecan;   Drug: Gemcitabine
7 Recruiting Feasibility of the Combination of Chemotherapy (Carbo/Caelyx or Carbo/Doxorubicin) With Tocilizumab (mAb IL-6R) and Peg-Intron in Patients With Recurrent Ovarian Cancer
Condition: Recurrent Ovarian Cancer
Interventions: Drug: tocilizumab and interferon alpha 2-b;   Drug: Carboplatin and Caelyx or doxorubicin
8 Recruiting Veliparib, Doxorubicin Hydrochloride, and Carboplatin in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
Conditions: Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Undifferentiated Adenocarcinoma;   Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer
Interventions: Drug: doxorubicin hydrochloride;   Drug: veliparib;   Drug: carboplatin;   Biological: bevacizumab;   Other: laboratory biomarker analysis
9 Unknown † A 2 Stage Trial of Lenalidomide (REV) in Asymptomatic Ovarian Cancer Patients With Increasing CA 125 in Late Relapse
Condition: Ovarian Cancer Recurrent
Intervention: Drug: Lenalidomide
10 Unknown † Combination Chemotherapy in Treating Older Patients With Metastatic Breast, Colorectal, or Ovarian Cancer That Cannot Be Removed by Surgery
Conditions: Breast Cancer;   Colorectal Cancer;   Ovarian Cancer
Interventions: Drug: capecitabine;   Drug: carboplatin;   Drug: fluorouracil;   Drug: oxaliplatin;   Drug: paclitaxel;   Drug: pegylated liposomal doxorubicin hydrochloride
11 Recruiting Carboplatin, Pegylated Liposomal Doxorubicin Hydrochloride, and Everolimus in Treating Patients With Relapsed Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
Conditions: Fallopian Tube Cancer;   Peritoneal Cavity Cancer;   Recurrent Ovarian Epithelial Cancer
Interventions: Drug: everolimus;   Drug: carboplatin;   Drug: pegylated liposomal doxorubicin hydrochloride;   Other: laboratory biomarker analysis
To Top

† Indicates status has not been verified in more than two years